Answer
Besponsa (inotuzumab ozogamicin) should be infused intravenously over 1.5 hours in children weighing less than 35 kg to mitigate QT prolongation risk; safety and efficacy in children under 1 year have not been established.
Sources for this answer
- BESPONSA 1 mg powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.2 Posology and method of administration · Version 12Document updated
Sources checked